Clinical Trials in Cerebrovascular Disease

The group participates in a number of acute and secondary prevention stroke clinical trials at local, national and international level, particularly acute stroke management and secondary prevention.

Clinical Trials

Acute Treatment

IMS III

A phase III randomised, multi-centre, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) an intra-arterial (IA) approach to recanalisation is superior to standard IV rTPA (Actilyse) alone when initiated within 3 hours of acute ischaemic stroke onset.

DIAS 3

A randomised, double blind, parallel group, placebo controlled phase III study to evaluate the efficacy and safety of Desmoteplase in subjects with acute ischaemic stroke within 3-9 hours after acute stroke onset.

INTERACT 2

A randomised trial to establish the effects of early intensive blood pressure lowering on death and disability in patients with stroke due to intracerebral haemorrhage. Lowering SBP <140mmHg within 1 hour compared to standard target of <180mmHg.

Stroke secondary prevention treatment

ROCKET-AF

A prospective, randomised, double-blind, double-dummy, parallel group, multicentre, event-driven, non-inferiority study comparing the efficacy and safety of once daily oral Rivaroxaban with adjusted dose oral Warfarin for the prevention of stroke and non-central nervous system systemic embolism in subject with non-valvular atrial fibrillation

PERFORM

Prevention of cerebrovascular and cardiovascular events of ischaemic origin with Terutroban in patients with a history of ischaemic stroke or transient ischaemic attack.

Imaging MRI studies

GADOVIST

A mulitcentre, randomised, double-blind, crossover, phase III study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast enchanced MRI of the central nervous system.

Research Staff

• Kitty Wong (clinical trial nurse team leader)